Lipid-lowering effects of gefarnate in statin-treated patients with residual hypertriglyceridemia:a randomized controlled study  

作　　者：Jing SHI Ming-Lu XU Mei-Jiao HE Wan-Lan BO Hai-Yu ZHANG Dang-Hui SUN Ding-Yu WANG Xiao-Yu WANG Qun SHAO Yu-Jiao PAN Yu ZHANG Chen-Guang DAI Jing-Ying WANG Lin-Wei ZHANG Guang-Zhong LIU Yue LI for the GPROT Study Group 

机构地区：[1]Department of Cardiology,the First Affiliated Hospital,Harbin Medical University,Harbin,China [2]Department of Gastroenterology,the Fourth Affiliated Hospital,Harbin Medical University,Harbin,China [3]Department of Cardiology,Harbin Medical University Cancer Hospital,Harbin,China [4]Department of Cardiology,Shenzhen People’s Hospital,Shenzhen,China [5]National Key Laboratory of Frigid Zone Cardiovascular Diseases,Harbin Medical University,Harbin,China [6]NHC Key Laboratory of Cell Transplantation,Key Laboratory of Cardiovascular Disease Acousto-Optic Electromagnetic Diagnosis and Treatment in Heilongjiang Province,Heilongjiang Province Clinical Medical Research Center for Hypertension,the First Affiliated Hospital,Harbin Medical University,Harbin,China [7]Institute of Metabolic Disease,Heilongjiang Academy of Medical Science,Harbin,China [8]不详

出　　处：《Journal of Geriatric Cardiology》2024年第8期791-798,共8页老年心脏病学杂志（英文版）

基　　金：supported by the State Key Program of National Natural Science Foundation of China(No.82330014);the Youth Program of the National Natural Science Foundation of China(No.81900374&No.82100455);the Postdoctoral Science Foundation of Heilongjiang Province(LBH-Z20175);the Key Research and Development Plan of Heilongjiang Province(2022ZX06C23&JD2023SJ44);the Outstanding Youth Science Foundation in the First Affiliated Hospital of Harbin Medical University(HYD2020YQ0002&HYD2024YQ16)。

摘　　要：BACKGROUND The prevention of coronary artery disease(CAD)faces dual challenges:the aspirin-induced gastrointestinal injury,and the residual cardiovascular risk after statin treatment.Geraniol acetate(Gefarnate)is an anti-ulcer drug.It was reported that geraniol might participate in lipid metabolism through a variety of pathways.The aim of this study was to assess the lipid-lowering effects of gefarnate in statin-treated CAD patients with residual hypertriglyceridemia.METHODS In this prospective,open-label,randomized,controlled trial,69 statin-treated CAD patients with residual hypertriglyceridemia were randomly assigned to gefarnate group and control group,received gefarnate(100 mg/3 times a day)combined with statin and statin alone,respectively.At baseline and after one-month treatment,the levels of plasma triglyceride,high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)and total cholesterol were tested.RESULTS After one-month gefarnate treatment,triglyceride level was significantly lowered from 2.64 mmol/L to 2.12 mmol/L(P=0.0018),LDL-C level lowered from 2.7 mmol/L to 2.37 mmol/L(P=0.0004),HDL-C level increased from 0.97 mmol/L to 1.17mmol/L(P=0.0228).Based on statin therapy,gefarnate could significantly reduce the plasma triglyceride level(P=0.0148)and increase the plasma HDL-C level(P=0.0307).Although the LDL-C and total cholesterol levels tended to decrease,there was no statistically significant difference.CONCLUSIONS The addition of gefarnate to statin reduced triglyceride level and increased HDL-C level to a significant extent compared to statin alone in CAD patients with residual hypertriglyceridemia.This suggested that gefarnate might provide the dual benefits of preventing gastrointestinal injury and lipid lowering in CAD patients.

关 键 词：NAT ALONE LIPID 

分 类 号：R541.4[医药卫生—心血管疾病]